IFNA1 and hematologic disorder: Panobinostat, a histone deacetylase inhibitor (HDACi) used in treating hematological malignancies and solid tumors (58), triggers the type I interferon (IFN) pathway and promotes AML cell differentiation and therapeutic advantages (59).